Clinical trial · Interventional
Application of ATP Infusions in Palliative Home Care
Application of Adenosine 5'-Triphosphate (ATP) Infusions in Palliative Home Care
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Palliative care in cancer aims at alleviating the suffering of patients. A previous study in patients with advanced non-small-cell lung cancer showed that adenosine 5'-triphosphate (ATP) infusions had a favourable effect on fatigue, appetite, body weight, muscle strength, functional status, quality of life, and survival. Based on these promising results, the present study was designed 1. To evaluate whether the beneficial effects of ATP administration observed in patients with advanced lung cancer would also be present in pre-terminal cancer patients of different tumour types, and 2. To test the feasibility of application of ATP infusions in a home care setting.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Palliative Care | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
| Survival | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adenosine 5'-triphosphate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- I
- interventionNames
- Drug: Adenosine 5'-triphosphate
- type
- NO_INTERVENTION
- label
- C
Primary outcomes (1)
- measure
- Survival Physical restriction Fatigue Quality of life
- timeFrame
- 0-8 weeks
Secondary outcomes (1)
- measure
- Appetite Nutritional intake Body height Body weight Triceps skin fold thickness Mid-upper arm circumference Strength of elbow flexor and knee extensor muscles Handgrip strength Process evaluation
- timeFrame
- 0-8 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * cytologically or histologically confirmed cancer * medical treatment options restricted to supportive care * a life expectancy \< 6 months * World Health Organization (WHO) performance status 1 or 2 * suffering from at least one of the following complaints: fatigue, weight loss \> 5% over the last 6 months, or anorexia Exclusion Criteria: * symptomatic angina pectoris * symptomatic heart failure * any form of atrioventricular (AV) block (assessed by electrocardiogram) * life expectancy \< 4 weeks * concurrent palliative chemotherapy * cognitive dysfunction, and other diseases hampering adequate follow up
References
Publications (3)
- BACKGROUNDAgteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5'-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000 Feb 16;92(4):321-8. doi: 10.1093/jnci/92.4.321. PMID 10675381
- BACKGROUNDAgteresch HJ, Rietveld T, Kerkhofs LG, van den Berg JW, Wilson JH, Dagnelie PC. Beneficial effects of adenosine triphosphate on nutritional status in advanced lung cancer patients: a randomized clinical trial. J Clin Oncol. 2002 Jan 15;20(2):371-8. doi: 10.1200/JCO.2002.20.2.371. PMID 11786563
- BACKGROUNDAgteresch HJ, Burgers SA, van der Gaast A, Wilson JH, Dagnelie PC. Randomized clinical trial of adenosine 5'-triphosphate on tumor growth and survival in advanced lung cancer patients. Anticancer Drugs. 2003 Sep;14(8):639-44. doi: 10.1097/00001813-200309000-00009. PMID 14501386